Silk Road Medical to Present at the Morgan Stanley 2020 Healthcare Conference
Silk Road Medical (Nasdaq: SILK), dedicated to stroke risk reduction, announced participation in the Morgan Stanley 2020 Healthcare Conference on September 18 at 11:45 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silk Road Medical (Nasdaq: SILK), dedicated to stroke risk reduction, announced participation in the Morgan Stanley 2020 Healthcare Conference on September 18 at 11:45 a.m. Eastern Time. The event will feature a live webcast accessible via the company's Investors section. Silk Road Medical’s flagship treatment, the TransCarotid Artery Revascularization (TCAR), effectively addresses carotid artery blockages, aiming for better patient outcomes.
Details
News Market Reaction – SILK
The recorded move for SILK in the trading session of this news was -5.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming Morgan Stanley 2020 Healthcare Conference.
Silk Road Medical’s management is scheduled to present on Friday, September 18 at 11:45 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.